Poolbeg Pharma PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POLBF research report →
About the company
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections.
- CEO
- Jeremy Skillington
- IPO
- 2022
- Employees
- 15
- HQ
- London, GB
Price Chart
- Market Cap
- $66.98M
- P/E
- -7.37
- P/S
- 0.00
- P/B
- 5.60
- EV/EBITDA
- -6.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -55.47%
- ROIC
- -73.60%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,694,077 · 1.66%
- EPS
- $-0.01 · 18.97%
- Op Income
- $-6,416,959
- FCF YoY
- -1.38%
- 52W High
- $0.12
- 52W Low
- $0.04
- 50D MA
- $0.08
- 200D MA
- $0.06
- Beta
- 1.82
- Avg Volume
- 1.08K
Get TickerSpark's AI analysis on POLBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our POLBF coverage
Recent articles, reports, and earnings notes.
No research on POLBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate POLBF report →Similar companies
Peers in the same neighborhood.